阿帕替尼在恶性肿瘤治疗中的临床应用

Clinical Application of Apatinib in Cancer Treatment

目的分析阿帕替尼在恶性肿瘤治疗中的临床效果。方法选取了46例晚期恶性肿瘤患者作为研究对象,其中胃癌患者每日1次,每次850 mg;肺癌和肝癌患者每日1次,每次750 mg;子宫内膜癌、乳腺癌、食管癌、肠癌患者每日1次,每次500 mg。如果患者出现不良反应,可以将药量降低500 mg或者是250 mg。用药2个月以后评估近期疗效,观察疗效。结果治疗后无完全缓解患者,3例部分缓解,进展26例,稳定17例,缓解率6. 52%,疾病控制率43. 48%。服用阿帕替尼在6个月以上的患者,其中位无进展生存期为7. 1个月,持续服用阿帕替尼在6个月以下的患者中位无进展生存期为3. 4个月,二者比较,P <0. 05,差异具有统计学意义。不良反应中以高血压、手足综合征、血小板减少、白细胞减少、蛋白尿、出血、乏力、恶心最为常见,其中发生率最高的为高血压。结论阿帕替尼对于恶性肿瘤的治疗有一定的效果,具有较高的耐受性。

Objective We aimed to study the clinical effect of apatinib in cancr treatment.Methods 46 patients with advanced cancer were identified for inclusion in this study.Patients with gastric cancer dosed 850 mg once a day,and lung cancer and liver cancer were 750 mg once a day.And patients with endometrial cancer,breast cancer esophageal cancer and intestinal cancer dosed 500 mg once a day.If toxicities were observed,the dosage can be reduced by 500 mg or 250 mg.We evaluated the short-term curative effect after 2 months,and observed the curative effect.Results After the treatment,we saw that no patients was completely alleviated,3 patients were partly alleviated,26 patients were at progressive stage,and 17 patients were in stable phase.The remission rate was 6.52%,and the disease control rate was 43.48%.The progressive-free survival(PFS)of patients who took apatinib for more than 6 months was 7.1 months,while of whom continued to took apatinib for less than 6 months was 3.4 months.The difference was significant(P<0.05).Hypertension,HFS,thrombocytopenia,leukocytopenia,proteinuria,hemorrhage,weakness and nausea were the most common adverse reactions,among which hypertension has the highest incidence.Conclusion Apatinib has certain effect on the treatment of cancer and has high tolerance.